Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Fallopian Tube Endometrioid Adenocarcinoma”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Early research (Phase 1)Study completedNCT01489371
What this trial is testing

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
Gynecologic Oncology Group 16
Large-scale testing (Phase 3)Active Not RecruitingNCT02446600
What this trial is testing

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated Carcinoma+10 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02283658
What this trial is testing

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous Cystadenocarcinoma+6 more
Mayo Clinic 20
Early research (Phase 1)Study completedNCT01459380
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Active Not RecruitingNCT02627443
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Metastatic Fallopian Tube CarcinomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI) 35
Large-scale testing (Phase 3)Active Not RecruitingNCT00565851
What this trial is testing

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Clear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+22 more
National Cancer Institute (NCI) 1,052
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Testing effectiveness (Phase 2)Ended earlyNCT04814875
What this trial is testing

Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+1 more
THERAPIM PTY LTD 16
Early research (Phase 1)Study completedNCT00006981
What this trial is testing

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Who this might be right for
Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT02068794
What this trial is testing

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+15 more
Mayo Clinic 34
Early research (Phase 1)Study completedNCT00006235
What this trial is testing

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Early research (Phase 1)Study completedNCT00003967
What this trial is testing

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group 24
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Study completedNCT00022347
What this trial is testing

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Study completedNCT00993616
What this trial is testing

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+7 more
National Cancer Institute (NCI) 29
Load More Results
579
87